Abstract: Described herein are compositions and methods relating to the use of a combination of live lactobacilli bacteria, particularly live Lactobacillus acidophilus, live Lactobacillus casei, and live Lactobacillus rhamnosus, for the relief of undesirable gastromtestmal health problems such as irritable bowel syndrome (IBS), abdominal pain, abdominal discomfort, bloating, liquid stools and constipation. This combination of live lactobacilli bacteria can also be used for improving quality of life of a subject suffering from IBS, for the relief of IBS, and/or for the prevention and/or treatment of IBS.

Abstract: The present invention broadly relates to the use of probiotics for the treatment and prevention of dermatitis. More particularly, the present invention relates to the use of a composition comprising Lactobacillus acidophilus strain I-1492 deposited at the CNCM, a Lactobacillus casei LBC80R® strain and a carrier for treating or preventing hand dermatitis.

Abstract: The present invention relates to an in vitro test by recombinant DNA technology for the evaluation of the potency of various angiotensin II (AII) antagonists on the inhibition of expression of angiotensinogen (ANG) gene in vivo. A transformed human liver cell line capable of expressing human angiotensinogen-growth hormone, which includes at least one DNA construct coding for at least a 5'-flanking region of the ANG operatively linked upstream to human growth hormone gene. An in vitro test for the evaluation of the potency of various angiotensin II (AII) antagonists on the inhibition of expression of angiotensinogen (ANG) gene in vivo, which comprises administering AII antagonists to a transformed human liver cell line of claim 1 and monitoring the expression of human angiotensinogen-growth hormone.